RxDoctor Payments Data

Keegan Zuk, MD

Urology · North Kansas City, MONPI 1427444678

Payments from drug & device makers

$8,001in general payments, 2019–2025

Across 223 payments — averaging $35.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$2K
  • Teleflex LLC$1K
  • AbbVie$566
  • Astellas Pharma US Inc$440
  • Antares Pharma, Inc.$327
  • Histosonics, Inc.$297
  • plus $3K from 43 others

What the payments were for

  • Travel & lodging$98412%
  • Food & beverage$6,76485%
  • Education$2533%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,001 in reported general payments places this provider in the 70th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$219,523
Medicare patients
548
Services billed
3,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron147$131,591
MyrbetriqMirabegron68$71,937
Tamsulosin Hcl472$7,557
Trospium Chloride ErTrospium Chloride14$4,300
Estradiol53$3,494
Solifenacin Succinate56$3,415
Testosterone21$2,311
Finasteride122$1,792
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst63$1,449
Trospium Chloride12$845
Potassium Citrate ErPotassium Citrate11$818
Silodosin12$807
Dutasteride18$540
Oxybutynin Chloride ErOxybutynin Chloride19$454
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen61$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$122$131,591147 claims
Astellas Pharma US IncMyrbetriq$440$71,93768 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 urology providers in Missouri.

Other urology in North Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →